Sun Pharma Advanced Research Company
Sun Pharma Advanced Research Company Ltd valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for Sun Pharma Advanced Research Company Ltd, framed against the sector median so the premium or discount is obvious at a glance.
Sun Pharma Advanced Research Company Ltd trades at a P/E of 4.68× and P/B of 5.42×.
Valuation
Profitability
Growth
Financial Health
Sun Pharma Advanced Research Company Ltd financials: P&L, balance sheet, cash flow, ratios.
Twelve years of audited numbers for Sun Pharma Advanced Research Company Ltd, switchable between annual and quarterly views, consolidated or standalone.
Sun Pharma Advanced Research Company Ltd reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹7,286.16 Cr and reported EPS of ₹47.86.
| Period | 2024 | 2025 | 2026 |
|---|---|---|---|
| Revenue from Operations | 76 | 72 | 1,879 |
| Other Income | 29 | 2 | 11 |
| Total Income | 105 | 74 | 1,890 |
| Cost of Goods Sold (COGS) | 28 | 23 | 24 |
| Gross Profit | 47 | 49 | 1,856 |
| +Operating Expenses | 450 | 372 | 257 |
| EBITDA | -402 | -323 | 1,599 |
| +Non-Operating Expenses | 14 | 21 | 32 |
| Profit Before Tax (PBT) | -387 | -343 | 1,553 |
| +Tax Expense | 0 | -0 | -0 |
| Profit After Tax (PAT) | -387 | -343 | 1,553 |
| Earnings Per Share (EPS) | -11.93 | -10.56 | 47.86 |
| Diluted Shares Outstanding (Nos.) | 32 | 32 | 32 |
| +Additional Disclosures | 520 | 439 | 351 |
| Sales Growth % | — | -5.00 | 2,518.32 |
| YoY Sales Growth % | — | -5.00 | 2,518.32 |
| Material Cost % | 37 | 32 | 1 |
| Employee Cost % | 188 | 214 | 6 |
| Other Cost % | 407 | 304 | 7 |
| OPM % | -532 | -450 | 85 |
| Tax % | -0 | 0 | -0 |
| Profit Growth % | — | 11.54 | 553.48 |
| Gross Margin % | 0.00 | 0.00 | 0.00 |
| EBITDA Margin % | -0.00 | -0.00 | 0.00 |
| Interest Coverage Ratio | -0.00 | -0.00 | 0.00 |
| Additional Fields | -415 | -336 | 1,589 |
Sun Pharma Advanced Research Company segment analysis: revenue and profit mix.
Disclosed business segments at Sun Pharma Advanced Research Company with their share of revenue and profit, switchable between consolidated and standalone reporting.
Sun Pharma Advanced Research Company discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
Sun Pharma Advanced Research Company Ltd investment thesis: bull case, bear case, and the flip lines.
Why someone would buy Sun Pharma Advanced Research Company Ltd, why someone wouldn't, and the quantitative tripwires that would force the call to flip.
Sun Pharma Advanced Research Company Ltd's investment case rests on 8 positive markers and 9 flagged concerns drawn from the latest reported filings.
What you're getting.
High promoter holding at 65.7% indicates strong leadership confidence.
Operates in the resilient Pharmaceuticals sector with consistent demand.
Robust clinical-stage pipeline targeting significant unmet medical needs.
Positive 45.90% quarterly profit variance hints at potential turnaround.
Growing global healthcare spending and demand for innovative treatments.
What can break it.
Deeply negative ROE (-84.04%) and ROCE (-279.00%) indicate severe unprofitability.
Significant decline in quarterly sales (-42.60%) and 3-year revenue growth (-19.44%).
Persistent negative cash flow per share (-11.42) indicates liquidity challenges.
Moderate debt-to-equity ratio (0.49) is concerning given ongoing losses.
High stock volatility and significant YTD price decline of -34.78%.
What would change my mind.
Trim if P/E re-rates above 6. The valuation cushion thins from there.
Reassess if quarterly profit growth prints below 0% for two consecutive quarters. The bull case relies on compounding earnings.
Watch interest coverage if debt-to-equity climbs above 42.28. Balance sheet risk re-prices growth multiples fast.
Exit if ROE slips below 272%. The operating engine is no longer compounding capital efficiently.
Sun Pharma Advanced Research Company Ltd peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — Sun Pharma Advanced Research Company Ltd is highlighted for quick read-across.
Quick Compare
Peer Comparison
Sun Pharma Advanced Research Company Ltd technical analysis: indicators, pivots and CPR.
Live RSI, MACD and moving-average signals plus today's pivot and Central Pivot Range levels for Sun Pharma Advanced Research Company Ltd — derived from the live tape, not yesterday's close.
Sun Pharma Advanced Research Company Ltd last traded at ₹223.76 with an intraday range of ₹205.81–₹224.52 — live indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Live: ₹223.76| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 267.67 | +43.91 | +19.62% |
| R3 | 248.96 | +25.20 | +11.26% |
| R2 | 236.74 | +12.98 | +5.80% |
| R1 | 230.25 | +6.49 | +2.90% |
| PIVOT | 218.03 | -5.73 | -2.56% |
| CURRENT | 223.76 | — | — |
| S1 | 174.12 | -49.64 | -22.18% |
| S2 | 192.83 | -30.93 | -13.82% |
| S3 | 199.32 | -24.44 | -10.92% |
| S4 | 211.54 | -12.22 | -5.46% |
SPARC is trading Above CPR, indicating Bullishness
CPR is Wider, suggesting unlikely for trending moves
Day's range: 205.81 ~ 210.4
Trading Above opening range, showing Bullishness
Sun Pharma Advanced Research Company Ltd delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for Sun Pharma Advanced Research Company Ltd over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in Sun Pharma Advanced Research Company Ltd stood at 32.6% of traded volume, against a 20-day average of 26.3%.
Sun Pharma Advanced Research Company announcements: results, concalls, ratings, M&A.
Filings Sun Pharma Advanced Research Company sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
Sun Pharma Advanced Research Company files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 73 documents below.
Copy of Newspaper Publication
Sun Pharma Advanced Research Company Limited has informed the Exchange about Copy of Newspaper Publication
Allotment of Securities
Sun Pharma Advanced Research Company Limited has informed the Exchange regarding allotment of 3,85,10,000 Warrants pursuant to Preferential Issue at…
Press Release
Sun Pharma Advanced Research Company Limited has informed the Exchange regarding a press release dated April 30, 2026, titled "SPARC Announces Sale…
Disclosure under SEBI Takeover Regulations
Dilip S. Shanghvi has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India…
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Sun Pharma Advanced Research Company Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018
Investor decks & rating reports.
Sun Pharma Advanced Research Company dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue Sun Pharma Advanced Research Company has declared, sequenced by announce and record date.
Sun Pharma Advanced Research Company corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About Sun Pharma Advanced Research Company Ltd: business, sector, key facts.
What Sun Pharma Advanced Research Company Ltd does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
Sun Pharma Advanced Research Company Ltd operates in the Healthcare, listed as NSE: SPARC, BSE: 532872.
SPARC (Sun Pharma Advanced Research Company Limited) is a clinical-stage biopharmaceutical company headquartered in Mumbai, India, focusing on the research and development of novel pharmaceutical products for global markets. Their core therapeutic areas of concentration are oncology, neurodegeneration, and immunology, reflecting a commitment to addressing significant unmet medical needs across diverse disease areas.
A significant portion of SPARC's business involves advancing a robust pipeline of drug candidates through various clinical trial phases. This includes Elepsia XR for epilepsy, PDP-716 for open-angle glaucoma, and Sezaby for neonatal seizures. These products represent different stages of development, highlighting SPARC's commitment to a diversified approach to drug discovery and development.
In the oncology space, SPARC is actively pursuing the development of Vodobatinib, a c-ABL inhibitor. This compound is in phase 2 clinical trials for Parkinson's disease, has completed phase 1 trials for Lewy body dementia, and is currently in preclinical development for Alzheimer's disease. Further, they are developing Vodobatinib (SCO-088), a BCR-ABL inhibitor, targeting refractory chronic myelogenous leukemia, also in phase 2 clinical trials.
SPARC's commitment to immunology is showcased by the development of Vibozilimod (SCD-044), a selective S1PR1 agonist currently in phase 2 trials for psoriasis and atopic dermatitis. The company also has preclinical stage candidates in development, including SCD-153 for alopecia areata and SBO-154, an anti-MUC-1 antibody-drug conjugate (ADC) targeting multiple tumor types. This demonstrates a long-term strategic vision for growth within this therapeutic area.
In summary, SPARC's business model centers on the innovative research, development, and clinical advancement of a diverse portfolio of pharmaceutical products across several key therapeutic areas. Their pipeline, ranging from preclinical to phase 2 trials, positions them for potential future growth and market expansion in the global biopharmaceutical industry. The company's focus on unmet medical needs underscores its commitment to improving patient outcomes.
Questions investors ask about Sun Pharma Advanced Research Company Ltd (SPARC).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of Sun Pharma Advanced Research Company Ltd (SPARC)?
The current share price of Sun Pharma Advanced Research Company Ltd (SPARC) is ₹223.76. Today, the stock has gained by ₹19.65 (9.63%), trading in a range of ₹205.81 to ₹224.52. The stock opened at ₹206.6 with a trading volume of 80,56,789 shares.
02Is Sun Pharma Advanced Research Company Ltd stock a good investment for long-term?
Sun Pharma Advanced Research Company Ltd can be considered for long-term investment based on several factors. The company has a market capitalization of ₹7,286.16 crores, P/E ratio of 4.68, ROE of 276.89%, and ROCE of -279.00%. The dividend yield stands at 0.00%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of Sun Pharma Advanced Research Company Ltd stock?
The 52-week high price of Sun Pharma Advanced Research Company Ltd (SPARC) is ₹0, while the 52-week low is ₹0. Currently trading at ₹223.76, the stock is Infinity% away from its 52-week low and -Infinity% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy Sun Pharma Advanced Research Company Ltd stock at the current price?
Whether to buy Sun Pharma Advanced Research Company Ltd stock at ₹223.76 depends on multiple factors. The stock is currently trading with a P/E ratio of 4.68 and P/B ratio of 5.42. Today's performance shows a gain of 9.63%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of Sun Pharma Advanced Research Company Ltd and when is the next dividend?
Sun Pharma Advanced Research Company Ltd offers a dividend yield of 0.00%, which means for every ₹100 invested at the current price of ₹223.76, you can expect to receive approximately ₹0.00 annually as dividends. The face value of the stock is ₹1.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of Sun Pharma Advanced Research Company Ltd?
Sun Pharma Advanced Research Company Ltd's key financial metrics include: P/E Ratio: 4.68, P/B Ratio: 5.42, ROE: 276.89%, ROCE: -279.00%, Dividend Yield: 0.00%, EPS: ₹47.86, Book Value: ₹41.25, and Debt-to-Equity: 41.78. The company's market cap stands at ₹7,286.16 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is Sun Pharma Advanced Research Company Ltd stock performing today in the market?
Sun Pharma Advanced Research Company Ltd stock opened at ₹206.6 and is currently trading at ₹223.76, showing a gain of ₹19.65 (9.63%). The intraday high is ₹224.52 and low is ₹205.81. The trading volume stands at 80,56,789 shares, indicating strong market participation today.
08What is the P/E ratio of Sun Pharma Advanced Research Company Ltd and what does it indicate?
Sun Pharma Advanced Research Company Ltd has a Price-to-Earnings (P/E) ratio of 4.68, which means investors are willing to pay ₹4.68 for every ₹1 of earnings. With an EPS of ₹47.86, this P/E ratio suggests the stock may be undervalued or facing growth challenges. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about Sun Pharma Advanced Research Company Ltd (SPARC) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- Aarey Drugs & Pharmaceuticals (AAREYDRUGS) Share PricePeer
- Aarti Drugs (AARTIDRUGS) Share PricePeer
- Aarti Pharmalabs (AARTIPHARM) Share PricePeer
- Ajanta Pharma (AJANTPHARM) Share PricePeer
- Akums Drugs & Pharmaceuticals (AKUMS) Share PricePeer
- Top Gainers TodayScreener
- Other undervalued NSE stocksScreener
- Quality + Value Portfolio strategyStrategy
- All Technical ScreenersScreener
- All Trading StrategiesStrategy